• SpacemiT

  Participated · Series B · Jan 2026

  Founded in November 2021, Hangzhou-based SpacemiT develops next-generation high-performance CPUs built on the open-standard RISC-V instruction set. Its chips are tailored for edge artificial intelligence workloads, enabling real-time processing on devices ranging from smart home products and smartphones to industrial sensors and autonomous robots. The company’s inaugural octa-core 64-bit RISC-V AI chip, the K1, launched in 2024 and has already shipped more than 150,000 units for open-source hardware, AI devices, and robotics applications. SpacemiT is currently preparing to mass-produce its second-generation K3 chip in April after completing tape-out last year. The firm provides integrated hardware-software optimization solutions that support large language model development and seeks to drive broader adoption of RISC-V within China’s growing AI ecosystem. Proceeds from its latest funding are earmarked for boosting the computing power of upcoming chips and expanding its engineering talent pool to capitalize on the surge in edge AI demand.

• Inventchip

  Participated · Series C · Sep 2025

  Founded in 2017, Inventchip is a Chinese integrated device manufacturer focused on silicon carbide (SiC) power semiconductors and related driver and control ICs. The company has mass-produced three generations of SiC MOSFETs that it says meet advanced industry performance standards. Its products are embedded in EV onboard chargers, DC-DC converters, e-drive systems, air-conditioning compressors, photovoltaics, energy storage units, charging piles and industrial power supplies. By 2024, Inventchip had shipped more than 16 million SiC MOSFETs, 18 million SiC Schottky barrier diodes and nearly 60 million driver ICs. The firm has also entered the EV main drive inverter market, securing projects with multiple automakers and suppliers. Proceeds from its latest financing will be used to expand SiC production capacity, accelerate product R&D and support broader market promotion.

• varnotech

  Participated · Series B · Mar 2024

  Huanaotai Biotech is an innovative vaccine and adjuvant developer focused on novel vaccine and adjuvant product development. The company is building core technology platforms to drive updates and replacement of domestically marketed vaccines. Its stated core platforms include an adjuvant technology platform, a vector technology platform, and an antigen screening technology platform. Huanaotai describes its adjuvant platform as having the potential to be disruptive in the domestic vaccine field. The company announced completion of a RMB 600 million B round.

No current team members are available.